Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 46,375

Document Document Title
WO/2014/101120
Disclosed are compounds of Formulae A defined herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A receptor.  
WO/2014/105620
Pregn-4-en-20-yn-3β-one is useful in the treatment of depressive disorders by nasal administration.  
WO/2014/102377
The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the presen...  
WO/2014/102588
The disclosure relates to indole-type piperidine compounds, indoline-type piperidine compounds and related piperidine-type bicyclic compounds containing a five-membered nitrogen- containing ring (e.g., pyrrole or dihydropyrrole) fused to...  
WO/2014/101373
Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds whic...  
WO/2014/104272
The present invention provides a cinnamic acid amide derivative having an excellent analgesic activity. The cinnamic acid amide derivative according to the present invention is a compound that exhibits an excellent analgesic activity on ...  
WO/2014/104372
Provided is a novel α-halogen substituted thiophene compound which has strong LPA receptor antagonist activity and is useful as a pharmaceutical product, or a pharmacologically acceptable salt thereof. A compound represented by general ...  
WO/2014/101113
Disclosed are compounds of Formula (A), as defined herein, which have binding activity for an A2A-receptor and are believed to be useful for treatment or management of CNS diseases or conditions which can be treated or managed using comp...  
WO/2014/105576
Provided herein are compositions comprising eicosapentaenoic acid (EPA) and polar lipids (e.g., glycolipids and phospholipids), and which do not contain any docosahexaenoic acid (DHA) or esterified fatty acids.  
WO/2014/102778
Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying a...  
WO/2014/106238
Provided herein are heterocyclyl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or manage...  
WO/2014/102339
The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H -benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions ...  
WO/2014/102233
The present invention relates to compounds of formula (I), wherein the substituents are described in claim 1 and to the pharmaceutically acceptable salts thereof. These compounds inhibit the enzyme catechol-O-methyltransferase (COMT). Th...  
WO/2014/101295
Disclosed is an isoxazole derivative that inhibits the activity of the Janus kinases (JAKs), the structure thereof as presented in formula I, formula II, formula IX, and formula XI. The substituent groups in the formulas are described in...  
WO/2014/097978
Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving the abnormal accumulation of amyloid β protein, which contains ILEI or a vector in which the polynucleotide encoding ILEI has been inserte...  
WO/2014/100227
Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and com...  
WO/2014/098831
Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen o...  
WO/2014/100601  
WO/2014/098306
The present invention relates to an acetylcholinesterase activity inhibitor, a pharmaceutical composition for preventing and/or treating dementia, and/or a cerebral nerve protective agent containing a compound derived from Hericium erina...  
WO/2014/100533
The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.  
WO/2014/097259
The present invention relates to a composition comprising a) an extract of a plant belonging to the genus Raphanus, wherein said extract is obtainable or obtained by extracting at least the air roots, seeds and/or bulbs with a hydrophili...  
WO/2014/097038
The present invention provides compounds of formula (I), wherein the variables R1, R2, R5 and b are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates...  
WO/2014/095088
The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to the epidermal growth factor receptor (EGFR) as a clinical target for treatment of neurolog...  
WO/2014/098098
A compound represented by formula (I) [wherein each symbol is as defined in the description] has a TRPA1 antagonistic activity, and the compound and a medicine containing the compound are useful for the prevention or treatment of disease...  
WO/2014/097474
Provided is a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. Formula (I) (In the formula: R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alke...  
WO/2014/100728
Provided is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the di...  
WO/2014/100022
A nutritional composition for use in enhancing learning and memory in an individual in need thereof which nutritional composition comprises at least one human milk oligosaccharide selected from lacto-N-neotetraose, lacto-N-tetraose, disi...  
WO/2014/096384
The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for treating...  
WO/2014/094041
The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment...  
WO/2014/098295
The present invention relates to a composition for preventing or treating oxidative brain damage and brain dysfunction, the composition comprising Astragalus membranaceus and Salvia miltiorrhiza as active ingredients. The composition acc...  
WO/2014/096321
The present invention relates to antibodies or fragments thereof that specifically bind to Tau phosphorylated at serine 422 (p S422), and to their use for treating and diagnosing Alzheimer's disease, Tauopathies and related Tau disorders.  
WO/2014/096418
The present invention relates to a pharmaceutical composition for use in the treatment or prevention of epilepsy, comprising a means for alleviating or reversing the effect of a dysregulation of a miRNA molecule. The invention further re...  
WO/2014/094623
Use of Tatarian Aster extract in preparing a medicament for treating pain and/or enhancing the analgesic effect of an opioid drug, the extract is extracted from fresh and/or dried roots and rhizomes of Tatarian Aster plant, in which the ...  
WO/2014/100353
8'-HydiOxy-Dihydroergotamine (8'-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or...  
WO/2014/100541
The present invention relates to compounds of Formula (I) wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase ("ASKl") inhibitory activity, and are thus useful in the treatment of ASKl -mediated ...  
WO/2014/096093
The present invention relates to a compound of formula (I') or a pharmaceutically acceptable salt, solvate or hydrate thereof, in which: X3 is F, OH or SH, Y3 is F, OH or SH, X1, X2, X4, X5, Υ1, Y2, Y4 and Y5 are, independently of one a...  
WO/2014/096373
The present invention refers to solid forms of agomelatine, a process for their preparation and pharmaceutical compositions containing them. The present invention also relates to a process for the manufacture of N-[2-(7-methoxy- -naphtha...  
WO/2014/096958
The present invention relates to the identification of novel compounds that counteract the formation of the Membrane Attack Complex (MAC) which is the terminal process during complement activation of the immune system, and that is involv...  
WO/2014/095774
The invention concerns BET-protein-inhibiting, in particular BRD4-inhibiting, dihydropyridopyrazinones of general formula (I), in which A, X, R1, R2, R3, R4, R5, R6, R7 and n have the meanings given in the description, intermediates for ...  
WO/2014/096402
The present invention relates to an enzyme having a NMDA antagonist activity and/or an anticholinergic activity, wherein said enzyme is selected from the group comprising phosphotriesterases and phosphotriesterases derivatives. The prese...  
WO/2014/100501
Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.  
WO/2014/100228
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...  
WO/2014/100624
A stable, non-aqueous, liquid pharmaceutical composition contains remifentanil dissolved in a non-aqueous solvent. The formulation is provided with a pH ranging from about 2.0 to about 3.5 and can be used as an injectable. A method for p...  
WO/2014/098249
The purpose of the present invention is to provide a composition having a tissue repairing activity that is capable of promoting a reaction relating to tissue repairing. Disclosed is a composition having an activity of repairing a tissue...  
WO/2014/095775
The invention concerns BET-protein-inhibiting, in particular BRD4-inhibiting, dihydroquinoxalinones of general formula (I), in which A, X, R1, R2, R3, R4, R5, R6, R7 and n have the meanings given in the description, intermediates for pro...  
WO/2014/098512
The present invention relates to a novel use of fucosterol for the treatment of neurodegenerative diseases, and more particularly, to a pharmaceutical composition and functional health food comprising fucosterol, as an active ingredient,...  
WO/2014/099696
The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatme...  
WO/2014/094664
The present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparin...  
WO/2014/100438
The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhib...  
WO/2014/100600
Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The a...  

Matches 251 - 300 out of 46,375